Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography.
Catherine G Fitzgerald DickmannAlexander Franklin McDonaldNhi HuynhAngela RigopoulosZhanqi LiuNancy GuoLaura D OsellameMichael A GormanMichael W ParkerHui Kong GanAndrew Mark ScottUwe AckermannIngrid Julienne Georgette BurvenichJonathan M WhitePublished in: Chemical communications (Cambridge, England) (2023)
Bromodomain and extraterminal (BET) proteins, a family of epigenetic regulators, have emerged as important oncology drug targets. BET proteins have not been targeted for molecular imaging of cancer. Here, we report the development of a novel molecule radiolabelled with positron emitting fluorine-18, [ 18 F]BiPET-2, and its in vitro and preclinical evaluation in glioblastoma models.
Keyphrases
- positron emission tomography
- computed tomography
- cancer therapy
- quantum dots
- pet imaging
- papillary thyroid
- pet ct
- palliative care
- gene expression
- dna methylation
- squamous cell
- living cells
- transcription factor
- fluorescent probe
- protein protein
- drug delivery
- cell therapy
- binding protein
- adverse drug
- lymph node metastasis
- drug induced
- mesenchymal stem cells
- clinical evaluation